Mecamylamine

Mecamylamine is an orally active, nonselective, noncompetitive nAChR antagonist. Mecamylamine is also a ganglionic blocker. Mecamylamine can across the blood-brain barrier. Mecamylamine can be used in the research of neuropsychiatric disorders, hypertension, antidepressant area[1][2][5].

Product Specifications

CAS Number

[60-40-2]

UNSPSC

12352211

Hazard Statement

H315, H319, H320

Target

Histamine Receptor; nAChR

Type

Reference compound

Related Pathways

GPCR/G Protein; Immunology/Inflammation; Membrane Transporter/Ion Channel; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/mecamylamine.html

Purity

90.0

Solubility

10 mM in DMSO

Smiles

CC1(C)C(NC)(C)C2CCC1C2

Molecular Formula

C11H21N

Molecular Weight

167.29

Precautions

H315, H319, H320

References & Citations

[1]Omar Hernández-González, et al. Mechanisms of stimulatory effects of mecamylamine on the dorsal raphe neurons. Brain Res Bull. 2020 Nov;164:289-298. |[2]C P Robinson, et al. The influence of mecamylamine on contractions induced by different agonists and on the role of calcium ions in the isolated rabbit aorta. J Pharmacol Exp Ther. 1976 Apr;197 (1) :57-65. |[3]Mahadevappa P Badanavalu, et al. Nicotine is neuroprotective to neonatal neurons of sympathetic ganglion in rat. Auton Neurosci. 2019 Jan;216:25-32. |[4]Katsuji Kiuchi, et al. Mecamylamine suppresses Basal and nicotine-stimulated choroidal neovascularization. Invest Ophthalmol Vis Sci. 2008 Apr;49 (4) :1705-11. |[5]Rabenstein RL, et al. The nicotinic antagonist mecamylamine has antidepressant-like effects in wild-type but not beta2- or alpha7-nicotinic acetylcholine receptor subunit knockout mice. Psychopharmacology (Berl) . 2006 Dec;189 (3) :395-401.

Shipping Conditions

Blue Ice

Storage Conditions

-20°C, 3 years (Powder)

Scientific Category

Reference compound1

Clinical Information

Launched

Citation 01

Nat Commun. 2023 Apr 17;14 (1) :2182.|Acta Pharmacol Sin. 2024 Jun;45 (6) :1160-1174.|bioRxiv. 2023 Jul 6.|bioRxiv. 2024 November 03.|Cell Biosci. 2024 Dec 3;14 (1) :146.